Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

Phase 2, Randomized, Double-Blind, Parallel-Group, Four Week, Efficacy And Safety Trial Of [S,S]-Reboxetine (PNU-165442g) And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

This study will compare the safety and efficacy of [S,S]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.

Inclusion Criteria:

1. Diagnosis of Attention Deficit Hyperactivity Disorder according to DSM-IV criteria.
2. Score of 24 or higher on the Adult ADHD Investigator Symptom Rating Scale
3. Score of 4 or higher on the Clinician Global Impression - Severity scale

Exclusion Criteria:

1. Significant comorbid psychiatric diagnoses
2. Significant risk of suicidal or violent behavior